Core Viewpoint - Longshen Rongfa (300534) reported a net profit increase of 27.48% for the first half of 2025, despite a decline in total revenue by 8.21% compared to the previous year [1] Financial Performance - Total revenue for the first half of 2025 was 496 million yuan, down from 541 million yuan in 2024, representing an 8.21% decrease [1] - Net profit attributable to shareholders reached 27.96 million yuan, up from 21.93 million yuan in 2024, marking a 27.48% increase [1] - The gross profit margin decreased to 66.19%, down 13.38% year-on-year, while the net profit margin increased to 8.25%, up 18.99% [1] - Total operating expenses (selling, administrative, and financial) amounted to 248 million yuan, accounting for 50.05% of revenue, a decrease of 20.43% [1] - Earnings per share rose to 0.09 yuan, a 27.52% increase from 0.07 yuan in 2024 [1] Cash Flow and Debt - Operating cash flow per share was -0.21 yuan, a significant decrease of 129.82% year-on-year, attributed to reduced sales collections and increased payments related to operating activities [1][3] - The company’s monetary funds decreased by 39.05% to 215 million yuan, while accounts receivable increased by 27.52% to 235 million yuan [1] Business Model and Product Development - The company relies heavily on research and marketing to drive performance, with a historical return on invested capital (ROIC) of 5.51%, indicating average capital returns [3] - Longshen Rongfa is focused on the development of its main products, including the unique "Yuanhu Zhitong Dwan," which has been recognized for its efficacy in treating various types of pain [5][6] - The company is actively pursuing the second development of major products and enhancing its technological barriers through various research projects [6] Market Strategy and Future Outlook - The company is optimistic about the health sector and is expanding its product offerings in this area, including various health products [7] - It aims to leverage its advantages in the traditional Chinese medicine industry, supported by recent government policies promoting the sector [9] - The company plans to enhance its quality management system and increase R&D investments to develop more high-quality products [9]

消息面上，陇神戎发在互动平台表示，截至2025年7月31日，公司股东户数为28，861户，较上期减少 1.05%。此外，公司新药研发进展受到市场关注，布瑞哌唑口溶膜临床试验仍在推进中。 资金方面，8月5日主力资金净流出3871.51万元，占流通市值的1.09%。近五日主力资金累计净流入 1277.98万元。 风险提示：股市有风险，投资需谨慎。 截至2025年8月5日收盘，陇神戎发股价报11.72元，较前一交易日下跌3.06%。当日成交额5.67亿元，换 手率达15.88%。 陇神戎发属于医药生物行业，主营业务为中成药、化学药的研发、生产和销售。公司控股子公司普安制 药开发的改良型新药布瑞哌唑口溶膜目前正在开展临床试验工作。 ...

Core Viewpoint - The company announced that its subsidiary, Puan Pharmaceutical, is currently conducting clinical trials for a modified new drug, Brupiprazole oral film [2] Group 1 - The modified new drug Brupiprazole oral film is under clinical trial [2] - Investors are encouraged to refer to the company's regular reports and announcements for detailed information on new drug development [2]

Group 1 - The company has a modified new drug, Bupropion oral film, currently undergoing clinical trials [2] - The company is responding to investor inquiries regarding its innovative drug development pipeline [2] - The company is focused on the future planning of innovative drugs [2]

Core Viewpoint - Longshen Rongfa (300534.SZ) is currently conducting clinical trials for its improved new drug, Brupaprazole oral film, developed by its subsidiary Puan Pharmaceutical [1] Group 1 - The company has provided updates on its new drug development through announcements on March 28 and July 30, 2025, available on the Giant Tide Information Network [1] - Investors are encouraged to refer to the company's regular reports and temporary announcements for detailed information regarding the new drug research and development [1]

Company Developments - Company announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received two Clinical Trial Supplement Approval Notices from the National Medical Products Administration on July 30 [1] - The approval allows for the continuation of clinical trials for the drug Brupiprazole oral film, specifically adding 0.5mg and 1mg specifications for the treatment of schizophrenia [1] - The company reported a revenue of 1.039 billion yuan for 2024, a decrease of 3.79% year-on-year, and a net profit attributable to shareholders of 25.8046 million yuan, down 58.14% year-on-year [2] Industry Insights - The company is optimistic about the prospects in the health sector and is actively developing health products, including Huangqi Danggui capsules and plant-based beverages [3] - Recent government policies have been introduced to support the innovation and development of traditional Chinese medicine, which is expected to enhance the quality and market demand for traditional Chinese medicine products [3] - The aging population is increasing the demand for disease prevention and chronic disease management, which is expected to further expand the market for traditional Chinese medicine products [3]

Core Viewpoint - Longshen Rongfa (300534.SZ) announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received two approval notices from the National Medical Products Administration for clinical trial supplement applications on July 30, 2025 [1] Group 1 - The clinical trial for the drug Bupropion oral dissolving film has been approved to add specifications of 0.5mg and 1mg [1] - Bupropion oral dissolving film is intended for the treatment of schizophrenia [1] - The supplement application primarily aims to increase the relevant specifications for the clinical trial, which will continue to be conducted [1] Group 2 - According to China's drug registration laws and regulations, after obtaining the clinical trial approval notice, the drug must undergo clinical trials and receive review and approval from the National Medical Products Administration before it can be produced and marketed [1]

Core Viewpoint - The company announced that its subsidiary, Puan Pharmaceutical, received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam in 0.5mg and 1mg specifications, which are intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of new specifications for the clinical trials of Brivaracetam, indicating ongoing development in the treatment of schizophrenia [1] - Clinical trials will continue following the approval, and the drug must undergo further evaluation and approval by the National Medical Products Administration before it can be manufactured and marketed [1]

Core Viewpoint - The company, Longshen Rongfa, announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam oral film, which is intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of two new specifications: 0.5mg and 1mg [1] - The supplementary application was accepted on May 20 and meets the requirements for drug registration [1] - The clinical trials for Brivaracetam oral film can continue as per the approved content [1]

Core Viewpoint - The company announced that its subsidiary, Puan Pharmaceutical, received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam oral film in 0.5mg and 1mg specifications, which are intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of new specifications for the clinical trial of Brivaracetam oral film [1] - The clinical trial work will continue following the approval, as per the requirements of China's drug registration laws and regulations [1] - The drug must undergo clinical trials and receive further review and approval from the National Medical Products Administration before it can be produced and marketed [1]